The year psychedelics went mainstream

from Axios Re:Cap · host Axios

Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022. Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.

Episode metadata supplied by the publisher feed · Published Dec 21, 2021

Embed this episode

Attribution link and audio player

Ready to play

The year psychedelics went mainstream

0:00 11:21

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Small Caps Canada Small Caps Canada The Small Caps podcast keeps stock market investors informed with the latest news by interviewing directors of Canadian listed small cap companies and financial market analysts

Frequently Asked Questions

How long is this episode of Axios Re:Cap?

This episode is 11 minutes long.

When was this Axios Re:Cap episode published?

This episode was published on December 21, 2021.

Can I download this Axios Re:Cap episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!